JPWO2022120370A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022120370A5 JPWO2022120370A5 JP2023533999A JP2023533999A JPWO2022120370A5 JP WO2022120370 A5 JPWO2022120370 A5 JP WO2022120370A5 JP 2023533999 A JP2023533999 A JP 2023533999A JP 2023533999 A JP2023533999 A JP 2023533999A JP WO2022120370 A5 JPWO2022120370 A5 JP WO2022120370A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- cells
- immune cell
- edited
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121206P | 2020-12-03 | 2020-12-03 | |
| US63/121,206 | 2020-12-03 | ||
| US202163201159P | 2021-04-15 | 2021-04-15 | |
| US63/201,159 | 2021-04-15 | ||
| US202163236167P | 2021-08-23 | 2021-08-23 | |
| US63/236,167 | 2021-08-23 | ||
| US202163264223P | 2021-11-17 | 2021-11-17 | |
| US202163264234P | 2021-11-17 | 2021-11-17 | |
| US63/264,223 | 2021-11-17 | ||
| US63/264,234 | 2021-11-17 | ||
| PCT/US2021/072715 WO2022120370A2 (en) | 2020-12-03 | 2021-12-02 | Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023552998A JP2023552998A (ja) | 2023-12-20 |
| JPWO2022120370A5 true JPWO2022120370A5 (https=) | 2024-12-10 |
| JP2023552998A5 JP2023552998A5 (https=) | 2024-12-10 |
Family
ID=81854915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533999A Pending JP2023552998A (ja) | 2020-12-03 | 2021-12-02 | 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240335536A1 (https=) |
| EP (1) | EP4255453A4 (https=) |
| JP (1) | JP2023552998A (https=) |
| AU (1) | AU2021392809A1 (https=) |
| CA (1) | CA3200367A1 (https=) |
| WO (1) | WO2022120370A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2021252804A1 (en) * | 2020-06-12 | 2021-12-16 | Nkarta, Inc. | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
| CN117384853B (zh) * | 2022-07-11 | 2025-12-19 | 士泽生物医药（苏州）有限公司 | 一种表达pvr的通用型细胞及其制备方法 |
| CN117384852B (zh) * | 2022-07-11 | 2026-01-16 | 士泽生物医药（苏州）有限公司 | 一种表达lgals9的通用型细胞及其制备方法 |
| WO2024030970A2 (en) * | 2022-08-03 | 2024-02-08 | Nkarta, Inc. | Genetic editing of target genes to enhance natural killer cell function |
| CN120092090A (zh) * | 2022-11-07 | 2025-06-03 | 上海先博生物科技有限公司 | 工程化嵌合抗原受体免疫细胞及其应用 |
| WO2024107891A2 (en) * | 2022-11-16 | 2024-05-23 | Nkarta, Inc. | Dosing regimens for combination therapies |
| CN115948341B (zh) * | 2022-11-28 | 2025-05-16 | 上海恩凯细胞技术有限公司 | 敲低nkg2a基因的car-免疫细胞及其用途 |
| US20240358758A1 (en) * | 2023-04-07 | 2024-10-31 | Nkarta, Inc. | Methods for treatment of autoimmune diseases |
| WO2025073908A1 (en) * | 2023-10-05 | 2025-04-10 | Onk Therapeutics Limited | Optimised il-15 constructs |
| WO2025146467A1 (en) | 2024-01-04 | 2025-07-10 | Onk Therapeutics Limited | Targeted il-15 construct delivery |
| WO2026041793A1 (en) * | 2024-08-23 | 2026-02-26 | BioNTech SE | Chimeric proteins comprising non-human protein domains for enhancing antigenicity |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX373460B (es) * | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| US10648020B2 (en) * | 2015-06-18 | 2020-05-12 | The Broad Institute, Inc. | CRISPR enzymes and systems |
| EP4043556B1 (en) * | 2015-06-30 | 2024-02-07 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
| KR102438360B1 (ko) * | 2016-03-04 | 2022-08-31 | 에디타스 메디신, 인코포레이티드 | 암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분 |
| JP2020503043A (ja) * | 2016-12-30 | 2020-01-30 | セルラリティ インコーポレイテッド | 遺伝子改変されたナチュラルキラー細胞 |
| WO2018195339A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| JP2021502077A (ja) * | 2017-11-06 | 2021-01-28 | エディタス・メディシン，インコーポレイテッド | 免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素 |
| EP3765608A4 (en) * | 2018-03-15 | 2022-01-12 | KSQ Therapeutics, Inc. | GENE REGULATORY COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY |
| MX2020011697A (es) * | 2018-05-03 | 2020-12-10 | Univ Texas | Células exterminadoras naturales diseñadas para expresar receptores de antígeno quimérico con bloqueo de punto de control inmunitario. |
| WO2020113029A2 (en) * | 2018-11-28 | 2020-06-04 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
| US20220133790A1 (en) * | 2019-01-16 | 2022-05-05 | Beam Therapeutics Inc. | Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance |
| EP3924467A1 (en) * | 2019-02-15 | 2021-12-22 | Editas Medicine, Inc. | Modified natural killer (nk) cells for immunotherapy |
| JP7629414B2 (ja) * | 2019-06-04 | 2025-02-13 | ンカルタ・インコーポレイテッド | 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ |
| WO2021252804A1 (en) * | 2020-06-12 | 2021-12-16 | Nkarta, Inc. | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
-
2021
- 2021-12-02 JP JP2023533999A patent/JP2023552998A/ja active Pending
- 2021-12-02 US US18/255,222 patent/US20240335536A1/en active Pending
- 2021-12-02 EP EP21901656.5A patent/EP4255453A4/en active Pending
- 2021-12-02 AU AU2021392809A patent/AU2021392809A1/en active Pending
- 2021-12-02 CA CA3200367A patent/CA3200367A1/en active Pending
- 2021-12-02 WO PCT/US2021/072715 patent/WO2022120370A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11001621B1 (en) | Trifunctional T cell-antigen coupler and methods and uses thereof | |
| US20240075143A1 (en) | Cd7-targeted engineered immune cell, chimeric antigen receptor, cd7 blocking molecule and use thereof | |
| US10561686B2 (en) | Modified cell expansion and uses thereof | |
| US11111298B2 (en) | T cell-antigen coupler with various construct optimizations | |
| JP6285553B2 (ja) | 抗ｃｄ３０キメラ抗原受容体およびその使用 | |
| CN110818802B (zh) | 一种嵌合t细胞受体star及其应用 | |
| JPWO2022120370A5 (https=) | ||
| US11406667B2 (en) | T cell-antigen coupler with various construct optimizations | |
| CN108138148B (zh) | T细胞的激活和扩增 | |
| JP2023053328A5 (https=) | ||
| CA3065126A1 (en) | Chimeric antigen receptor cell preparation and uses thereof | |
| KR20230066007A (ko) | 신규한 보조자극 도메인을 포함하는 키메라 항원 수용체 및 이의 용도 | |
| US20220133792A1 (en) | Signaling platforms for chimeric antigen receptor t cells | |
| CA3078637A1 (en) | T cell-antigen coupler with y182t mutation and methods and uses thereof | |
| CN117187185A (zh) | 一种工程化免疫细胞及其用途 | |
| CN113166228A (zh) | 用于治疗b细胞恶性肿瘤的cd22特异性t细胞受体和过继性t细胞疗法 | |
| CN115873801A (zh) | 工程化免疫细胞及其用途 | |
| Morse et al. | Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes | |
| Friedmann-Morvinski et al. | Adoptive immunotherapy of cancer using effector lymphocytes redirected with antibody specificity |